Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Clinical trial NCT04681105 · COMPLETED

Trial details

NCT number: NCT04681105
Sponsor: City of Hope Medical Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Acute Leukemia Recurrent B Acute Lymphoblastic Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hairy Cell Leukemia Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Recurrent T Acute Lymphoblastic Leukemia Refractory Acute Leukemia Refractory B Acute Lymphoblastic Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Start date: 2020-11-18
Primary completion: 2025-08-05
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.